Home  »  Company   »  Now Is A Good Time To Buy Stoke Therapeutics Inc. ...

Now Is A Good Time To Buy Stoke Therapeutics Inc. (NASDAQ: STOK)

During the last session, Stoke Therapeutics Inc. (NASDAQ:STOK)’s traded shares were 0.11 million. At the end of the trading day, the stock’s price was $16.79, reflecting an intraday gain of 2.69% or $0.44. The 52-week high for the STOK share is $33.06, that puts it down -96.9 from that peak though still a striking 43.12% gain since the share price plummeted to a 52-week low of $9.55. The company’s market capitalization is $684.70M, and the average intraday trading volume over the past 10 days was 0.19 million shares, and the average trade volume was 292.43K shares over the past three months.

Stoke Therapeutics Inc. (NASDAQ:STOK) trade information

Stoke Therapeutics Inc. (STOK) registered a 2.69% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 2.69% in intraday trading to $16.79 this Friday, 08/05/22, hitting a weekly high. The stock’s 5-day price performance is 13.52%, and it has moved by 15.87% in 30 days. Based on these gigs, the overall price performance for the year is -37.40%. The short interest in Stoke Therapeutics Inc. (NASDAQ:STOK) is 5.84 million shares and it means that shorts have 21.28 day(s) to cover.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .


Stoke Therapeutics Inc. (STOK) estimates and forecasts

Statistics show that Stoke Therapeutics Inc. has underperformed its competitors in share price, compared to the industry in which it operates. Stoke Therapeutics Inc. (STOK) shares have gone down -2.95% during the last six months, with a year-to-date growth rate less than the industry average at -20.51% against 1.00. Yet analysts are ramping up their growth forecast for the fiscal year 2022. Revenue is predicted to shrink -15.00% this quarter and then drop -16.40% in the quarter after that.

Revenue for the current quarter is expected to be $2.35 million as predicted by 9 analyst(s). Meanwhile, a consensus of 9 analyst(s) estimates revenue growth to $2.51 million by the end of Sep 2022.

While earnings are projected to return -49.70% in 2022.

STOK Dividends

Stoke Therapeutics Inc. is due to release its next quarterly earnings between March 07 and March 11. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

Stoke Therapeutics Inc. (NASDAQ:STOK)’s Major holders

Stoke Therapeutics Inc. insiders own 6.29% of total outstanding shares while institutional holders control 105.26%, with the float percentage being 112.33%. Skorpios Trust is the largest shareholder of the company, while 163 institutions own stock in it. As of Mar 30, 2022, the company held over 14.44 million shares (or 36.90% of all shares), a total value of $304.04 million in shares.

The next largest institutional holding, with 3.64 million shares, is of RTW Investments LP’s that is approximately 9.31% of outstanding shares. At the market price on Mar 30, 2022, these shares were valued at $76.71 million.

Also, the Mutual Funds coming in first place with the largest holdings of Stoke Therapeutics Inc. (STOK) shares are Vanguard Total Stock Market Index Fund and Fidelity Select Portfolios – Biotechnology. Data provided on Mar 30, 2022 indicates that Vanguard Total Stock Market Index Fund owns about 0.62 million shares. This amounts to just over 1.57 percent of the company’s overall shares, with a $12.96 million market value. The same data shows that the other fund manager holds slightly less at 0.53 million, or about 1.35% of the stock, which is worth about $6.38 million.

Leave a Comment

Your email address will not be published.

On Key

Related Posts